A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Janssen launches ‘That’s My Word’ health equity campaign with radio host D.L. Hughley to raise awareness about multiple myeloma in Black communities; 20% of the 35,000 people in US diagnosed with multiple myeloma every year are Black
Published: March 02, 2023 by Johnson & Johnson Services Inc.
Janssen submits NDA to the US FDA seeking approval of niraparib and abiraterone acetate dual-action tablet, plus prednisone, as a first-line targeted treatment for patients with BRCA-positive metastatic castration-resistant prostate cancer
Published: March 01, 2023 by Johnson & Johnson Services Inc.
Janssen receives positive CHMP opinion for AKEEGA niraparib and abiraterone acetate dual action tablet plus prednisone or prednisolone to treat adult patients with BRCA1/2 gene-mutated metastatic castration resistant prostate cancer
Published: February 27, 2023 by Johnson & Johnson Services Inc.
Janssen to present data demonstrating its ambition to transform prostate and bladder cancer treatment through precision medicine, early intervention at ASCO in San Francisco, California, February 16-18
Published: February 14, 2023 by Johnson & Johnson Services Inc.
Roche expands agreement with Janssen Biotech to create companion diagnostics for targeted therapies; diagnostics technologies to include immunohistochemistry, digital pathology, next-generation sequencing, polymerase chain reaction, immunoassays
Published: February 14, 2023 by Marketline - Deals

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count